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Abstract
Carcinoma-associated fibroblasts are key contributors of the tumor microenvironment that regulates carcinoma
progression. They consist of a heterogeneous cell population with diverse origins, phenotypes, and functions.
In the present report, we have explored the contribution of bone marrow (BM)–derived cells to generate different
fibroblast subsets that putatively produce the matrix metalloproteinase 13 (MMP13) and affect cancer cell invasion. A
murine model of skin carcinoma was applied to mice, irradiated, and engrafted with BM isolated from green fluores-
cent protein (GFP) transgenic mice. We provide evidence that one third of BM-derived GFP+ cells infiltrating the tumor
expressed the chondroitin sulfate proteoglycan NG2 (pericytic marker) or α-smooth muscle actin (α-SMA, myofibro-
blast marker), whereas almost 90% of Thy1+ fibroblasts were originating from resident GFP-negative cells. MMP13-
producing cells were exclusively α-SMA+ cells and derived from GFP+ BM cells. To investigate their impact on tumor
invasion, we isolatedmesenchymal stem cells (MSCs) from the BMofwild-type andMMP13-deficientmice.Wild-type
MSC promoted cancer cell invasion in a spheroid assay, whereas MSCs obtained from MMP13-deficient mice failed
to. Our data support the concept of fibroblast subset specialization with BM-derived α-SMA+ cells being the main
source of MMP13, a stromal mediator of cancer cell invasion.
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Introduction
Carcinoma growth and metastatic dissemination are dependent on
the formation of a permissive tumor stroma composed of extracellular
matrix (ECM) and heterogeneous population of activated stromal
cells, including fibroblasts, endothelial cells, immune cells, and bone
marrow (BM)–derived stem and progenitor cells [1,2]. These tumor-
supporting stromal cells communicate with cancer cells through both
paracrine and juxtacrine signals mediated by ECM component depo-
sition, remodeling enzyme production, and growth factor or cytokine/
chemokine secretion. The interactions occurring between tumor cells
and host cells support blood vessel formation, promote the breakdown
of physical matrix barrier, endow cancer cells with proliferative and
invasive properties, and contribute to tumor cell attraction to distant
organs [3].
Carcinoma-associated fibroblasts (CAFs) constitute the majority of
stromal cells within the primary tumor in various types of carcinomas
[4,5]. The term CAF remains poorly defined and covers a heteroge-
neous population of stromal cells displaying various phenotypes [5–7]
that originate and develop mainly from the following three sources:
1) the recruitment of resident fibroblasts or stem cells from the sur-
rounding tissue, 2) the epithelial-to-mesenchymal transition [8], or
3) the recruitment of BM-derived cells [9]. Studies on murine models
have provided evidence that at least a portion of mesenchymal cells
originates from BM-derived mesenchymal stem cells (MSCs) [10–12].
In in vitro experiments, human MSCs exposed to tumor-conditioned
medium over a prolonged period of time have been shown to assume
a CAF-like myofibroblastic phenotype, suggesting that MSCs are a
source of CAFs and can be used in the modeling of tumor-stroma inter-
actions [13]. It is, however, not known whether these fibroblast sub-
populations are equally important to support tumor progression or
whether certain subpopulations contribute to specific steps of tumor
growth, invasion, and metastases. Notably, the elegant study of Karnoub
et al. has highlighted the contribution of MSCs to metastatic dissemina-
tion of cancer cells [14]. HowMSCs endowmalignant cells with a meta-
static potential is still not fully understood.
CAFs acquire a reactive phenotype similar to fibroblasts observed
during wound healing with the difference that they remain constantly
activated [15]. Activated fibroblasts are commonly identified by their
expression of α-smooth muscle actin (α-SMA), leading to the term
“myofibroblasts.” They synthesize a large amount of ECM compo-
nents [4] and contribute to ECM turnover by secreting a number
of ECM-degrading proteases such as the matrix metalloproteinases
(MMPs) [16]. Among MMPs, the collagenase subfamily contributes
to matrix remodeling by their ability to degrade fibrillar collagens
[16]. This subfamily includes the fibroblast interstitial collagenase
(MMP1), neutrophil collagenase or collagenase 2 (MMP8), and col-
lagenase 3 (MMP13). In addition, MMP14 (MT1-MMP) and gela-
tinases A and B (MMP2 and MMP9) display collagenolytic activities
[17,18]. These enzymes might exert opposite functions during cancer
progression, as some of them (e.g., MMP8) have a protective role in
cancer [19], whereas others (e.g., MMP1 andMMP13) promote tumor
progression [20].
The human form of MMP13 was initially identified in breast cancer
tissue [21] and has been detected in a large set of invasive neoplastic
tumors [22–26]. MMP13 expression is detected in tumor cells at the
invading front [22] and in stromal fibroblasts adjacent to tumor cells
[26]. The mouse counterpart of MMP13 is also strongly expressed in
the stroma of breast cancer xenografted tumor [27] and mammary
carcinomas [28]. In a xenograft mouse model of skin squamous cell
carcinoma, MMP13 was shown to enhance tumor growth and to pro-
mote angiogenesis through the release of vascular endothelial growth
factor from the ECM, thus allowing the invasive growth of skin squa-
mous carcinoma cells [29]. The implication of BM-produced MMP13
in angiogenesis was also pointed out during choroidal neovasculariza-
tion in a mouse model of age-related macular degeneration [30].
In the present study, we investigated the involvement of BM-
derived MSCs in the establishment of skin carcinoma-associated fibro-
vascular network. By studying different mesenchymal markers, as the
fibroblast marker Thy1, the myofibroblast marker α-SMA, and the
perivascular marker NG2, we provide evidence that BM-derived MSCs
contribute to fibroblastic populations associated with the connective
travea as well as to pericytic subpopulation surrounding blood vessels.
Notably, we provide evidence that MMP13 is produced by a special-
ized subset of tumor-infiltrating myofibroblasts expressing α-SMA and
derived from BM-MSCs.
Materials and Methods
Transgenic Mice
Transgenic mice heterozygous for the enhanced green fluorescent
protein (GFP) under the control of β-actin promoter C57BL/6-Tg
(ACTbEGFP)10sb were obtained from Jackson Laboratories (Bar
Harbor, ME). Homozygous Mmp13-deficient mice (Mmp13−/−)
and the corresponding wild-type mice (WT) were generated in
C57BL/6 background as previously described [30,31]. Mouse experi-
mental procedures were performed in accordance with the guidelines of
the University of Liège regarding the care and use of laboratory animals.
MSC Isolation and Characterization
MSCs were isolated from the BM and compact bones, isolated from
8- to 10-week-old mice, by crushing the mouse femurs and tibias with
mortar and pestle in phosphate-buffered saline (PBS) containing 2%
FBS and 1 mM EDTA. Cell suspension was collected and the remain-
ing bone fragments were incubated in 0.25% collagenase 1a (Sigma-
Aldrich, St Louis, MO) in PBS containing 20% FBS at 37°C. After
45 minutes of incubation, the cells were harvested, pooled with the
initial cell suspension, and cultured in mouse MesenCult medium
(STEMCELL Technologies, Grenoble, France) under hypoxic condi-
tions (5% O2). The cells were checked for MSC marker expression
(CD106+, Sca1+, CD34−, CD45−, and CD11b−) by flow cytometry
and for their capacity to differentiate into adipocytes, osteocytes, and
chondrocytes, as previously described [30]. We consider a culture as
being MSC when at least 90% of cells express CD106 and Sca1 and
do not express CD34, CD45, and CD11b. Moreover, the cells must
differentiate into adipocyte, osteocyte, or chondrocyte when cultured in
appropriate medium.The colony forming unit–fibroblast (CFU-F) assay
was used as a functional method to quantify MSCs [32]. MSCs were
used between passages 5 and 10.
BM Transplantation
BM cells were isolated from the tibia and femur of 8- to 10-week-old
donor GFP mice, by slowly flushing Dulbecco’s modified Eagle’s
medium (DMEM) culture medium (Gibco BRL, Paisley, United
Kingdom) inside the diaphyseal channel and then intravenously injected
into 8- to 10-week-old recipient C57Bl/6 mice (107 BM cells per ani-
mal), which before had been sublethally irradiated with a single dose of
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9 Gy. The success of BM transplantation was assessed by flow cyto-
metry on blood and BM samples were collected at the end of the
experiment to determine the percentage of GFP+ cells. For all assays,
similar percentage of BM reconstitution (around 70%) was observed.
Engraftment of MSCs was assessed through MSC isolation and char-
acterization, as described above, 5 weeks after the graft. In vitro CFU-F
assay revealed that one third ofMSCs were GFP+ cells (data not shown).
Subcutaneous Tumor Injection Model
Malignant murine keratinocytes (PDVA cells) were generated by
in vitro treatment of B10LP mouse keratinocytes with a carcinogen
(7,12-dimethylbenz(a)antracene) [33]. Five weeks after BM trans-
plantation (described above), the PDVA cancer cells (106 cells/injection)
were subcutaneously injected in both flanks of the mouse (n = 33).
On day 45, the tumors were resected, fixed in 4% paraformaldehyde,
incubated in 30% sucrose solution, and frozen in cold 2-methyl-
butane for cryostat sectioning (6 μm in thickness) or fixed in 4%
formamide for paraffin embedding.
Immunohistochemistry
For immunofluorescence, cryostat sections were fixed in 4% para-
formaldehyde before incubation with primary antibodies. Antibodies
raised against NG2 chondroitin sulfate proteoglycan (rabbit anti-rat
antibody; Chemicon, Temecula, CA), α-SMA/Cy3 (Sigma-Aldrich),
and Thy1 (rat anti-mouse antibody; BD Pharmingen, Franklin
Lakes, NJ) were incubated for 1 hour at room temperature. After
washings, the secondary swine anti-rabbit antibody conjugated to
Texas Red was applied for NG2 labeling (Dako, Glostrup, Denmark)
for 30 minutes. For Thy1 labeling, slides were incubated with biotin-
coupled rabbit anti-rat antibody (Dako) for 30 minutes, washed, and
incubated with streptavidin/Alexa Fluor 555 (Invitrogen, Carlsbad,
CA) for 30 minutes.
For combination of GFP immunoperoxidase with hematoxylin
and saffron staining, cryostat sections were first incubated with anti-
GFP antibodies (rabbit polyclonal antibody, 1/200; Abcam, Cambridge,
United Kingdom) for 1 hour, followed by incubation with swine anti-
rabbit HRP (Dako). After Mayer’s hematoxylin (Biogenex, Fremont,
CA) coloration, the slides were dehydrated in ethanol and stained for
30 minutes with alcoholic safranin O (0.6% safranin in 20% ethyl
alcohol; Sigma-Aldrich) before mounting.
For quantitative measurements of BM-derived cell infiltration in
the tumor, automatic computer-assisted image analysis was done
on images obtained after double immunostainings (five sections
per tumor, number of tumors = 8). Original stained images were reg-
istered in red-green-blue. Red and green image components were
processed independently and transformed in gray level images. Each
component was binarized using an automatic threshold to extract
cells from the background. The areas occupied by each cell subtype
as well as the intersection areas were calculated. Results are presented
as the common area occupied by BM-derived GFP+ cells (in green)
and immunostained cells (cells positive for α-SMA, NG2, or Thy1;
in red) reported to the immunostained area. The relevance of the
image analysis applied here was assessed by a multiscale validation
(at 10- and 20-fold magnification). Results presented are those obtained
at 10-fold magnification.
23.7%
GFP
A.
C.
B.
D.
200μm
100μm
200μm
200μm
GFP+ cells positive for CD45+ : 61,2 %
GFP
Figure 1. BM-derived cells recruited in the stroma of skin tumors. PDVA malignant keratinocytes were transplanted into mice engrafted
with BM from GFP transgenic mice. (A) Intense desmoplastic reaction evidenced within the skin tumor by collagen staining using saffron
coloration (yellow). (B) GFP+ BM–derived cells recruited in the tumor. Flow cytometry analysis of cells isolated from the tumor through
enzymatic dissociation revealing that 23.7% of cells were GFP+ (insert). (C) Combined GFP immunoperoxidase staining of GFP+ cells
(brown) and collagen deposition through saffron coloration (yellow). (D) Detection of GFP positivity (green) and immunostaining for CD45+
inflammatory cells (red). A higher magnification is shown (insert). The percentage of CD45+ cells expressing GFP was assessed by a
computerized method of quantification.
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In Situ Hybridization
Antisense and sense MMP13 riboprobes were generated from plas-
mid pCLM11-810 [34] as previously described [35]. The exposure
time in nuclear emulsion (ILFORD Imaging UK Limited, Mobberley,
United Kingdom) was 7 days. Combined immunohistochemistry and
in situ hybridization were performed according to Illemann et al. [36].
Hence, before the in situ hybridization, the primary antibody [α-SMA/
fluorescein isothiocyanate (FITC; Sigma-Aldrich) or GFP (Abcam)]
diluted in PBS containing 1% RNAse inhibitor was incubated for
2 hours at room temperature (Roche, Basel, Switzerland). Incubation
with radiolabeled probe (sense or antisense) was then performed as
specified above. Finally, the sections were counterstained with Mayer’s
hematoxylin, dehydrated with ethanol, and mounted.
To determine the distribution of MMP13 mRNAs in relation with
α-SMA+ or GFP+ cells detected by immunohistochemistry, we applied
a computer-assisted quantification method described previously [37].
The skeleton of immunopositive stromal compartment was first delin-
eated. The density of black spots (MMP13 mRNAs) was then calcu-
lated in successive rings obtained by the dilatation 1, 2, …, n times of
these skeletons. The density of labeling cells is represented in a function
of the distance to stromal compartment skeleton.
Tumor Cell Dissociation and Flow Cytometry Analysis
Whole tumor samples were cut into small pieces and treated dur-
ing 30 minutes at 37°C with type 1a collagenase from Clostridium
histolyticum (400 U/ml; Sigma-Aldrich) and DNAse (1 mg/ml;
Roche) to dissociate the tumor into single-cell suspension. The cell
suspension was filtered (40-μm cell strainer; BD Falcon, San Jose,
CA) and analyzed by flow cytometry for GFP expression using a
FACSCanto II cell sorter (BD Biosciences, San Jose, CA).
Confrontation of Tumor Cells and MSC in Culture
Multicellular spheroids were generated by seeding 2000 PDVA cells
alone or with 2000MSCs in each well of nonadherent round-bottomed
96-well plates, in DMEM (Gibco BRL) containing 2%FBS and 0.24%
high-viscosity methylcellulose (Sigma-Aldrich). After 24 hours of cul-
ture, spheroids were collected (maximum of eight per well), embedded
in collagen gels in 48-well plates, and maintained in 2%FBSDMEMat
37°C for 48 hours. In some assays, a broad-spectrum hydroxamic acid–
based syntheticMMP inhibitor BB-94 [38] was added at a final concen-
tration of 5 μM in the collagen gel and in the culture medium. Cells
were examined under a Zeiss Axiovert 25 microscope equipped with
an Axiocam Zeiss camera and KS 400 Kontron image analysis software
(Carl Zeiss Microscopy, Zaventem, Belgium). Images were processed
using ImageJ program to become binary images in which the value of
1 was attributed for cells and the value of 0 for the background. Results
are presented as the total migrating cell area reported to spheroid area. In
co-culture assays, MSCs were cultured on six-well plates (250,000 cells/
well) in the absence or presence of a 0.4-μmpore size insert (Greiner Bio
One, Alphen aan den Rijn, The Netherlands) containing PDVA cells
(50,000 cells/insert). These inserts allow the passage of soluble factors
but not cells to migrate. After 3 days of culture, MSCs were harvested
for protein or RNA extractions.
RNA Extraction and Reverse Transcription–Polymerase
Chain Reaction
Total RNA from MSC and PDVA cells were extracted using the
High Pure RNA Isolation Kit (RocheDiagnostics,Mannheim, Germany)
according to the manufacturer’s protocol. Reverse transcription–
polymerase chain reaction (RT-PCR) was performed using an amplifi-
cation kit (GeneAmp Thermostable rTth Reverse Transcriptase RNA
Figure 2. Characterization of BM-derived fibroblastic cell subsets in the tumor. PDVA malignant keratinocytes were subcutaneously
transplanted into both flanks of mice, which have been engrafted with BM derived from GFP transgenic mice. Representative images
of cryosections of squamous cell carcinoma tumor tissue infiltrated with GFP+ BM–derived cells (green) and immunostained for the
presence of (A) α-SMA, (B) NG2, and (C) Thy1 (red). A higher magnification is shown (insert). (D) Computerized quantification of the co-
localization of GFP signal with α-SMA, NG2, and Thy1 immune signals.
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PCR Kit; Roche, Branchburg, Germany). Specific pairs of primers
(Eurogentec, Seraing, Belgium) for mouse MMP13 were designed as
follows: forward (exon 6), 5′-ATGATCTTTAAAGACAGATTCT-
TCTGC-3′; reverse (exon 7), 5′-TGGGATAACCTTCCAGA-
ATGTCATAA-3′. Amplification of 32 cycles was run for 15 seconds
at 94°C, 20 seconds at 68°C, and 30 seconds at 72°C followed by a final
2-minute extension step at 72°C. RT-PCR products were resolved in
10% acrylamide gels and analyzed with a fluorescence imager (LAS-
4000; Fujifilm, Tokyo, Japan) after staining with Gel Star (Cambrex,
East Rutherford, NJ). Gene expression levels were measured as a ratio
between expression values and internal 28S.
Protein Extraction and Western Blot
After cell incubation in ice-cold lysis buffer (1% Triton X-100,
150 mM NaCl, 1% IGEPAL-CA 630, 1% sodium deoxycholate,
0.1% sodium dodecyl sulfate (SDS), complete) for 30 minutes, cell
lysates were clarified by centrifugation at 12,000 rpm at 4°C for
30 minutes and stored frozen at −20°C. Protein concentration was
determined by using DC Protein Assay Kit (Bio-Rad Laboratories,
Hercules, CA). Protein samples were electrophoresed on gradient
sodium dodecyl sulfate–polyacrylamide gel and subsequently trans-
ferred to polyvinylidene fluoride membranes. Membranes were treated
with blocking buffer [PBS 0.1%Tween-20 (Merck,Whitehouse Station,
NJ), 1% casein (Sigma-Aldrich)] for 1 hour at room temperature and
followed by incubation with a sheep anti-mouse MMP13 (sheep poly-
clonal to MMP13 diluted 1/700; Abcam) overnight at 4°C. After exten-
sive washings, membranes were incubated for 1 hour with secondary
HRP antibodies (rabbit anti-sheep/HRP diluted 1/2000; Dako). Bands
were detected by chemiluminescence using an Enhanced Chemilumi-
nescence Kit (Perkin Elmer Life Sciences, Boston, MA) according to
the manufacturer’s instructions. Subsequent detection of actin (rabbit
anti-actin; Sigma-Aldrich) was performed on the same filters as control.
Statistical Analysis
Data were analyzed with GraphPad Prism 4.0 (San Diego, CA). The
Mann-Whitney test was used to determine whether differences between
experimental groups could be considered as significant (P < .05).
Results
BM-derived Cells Recruited in the Tumor Stroma Fuel the
Generation of CAFs with Different Phenotypes
To determine how BM-derived cells contribute to stromal support
in tumor growth of squamous cell carcinoma of the skin, we used a
murine malignant keratinocyte cell line (PDVA) transplantation
mouse model in C57Bl/6 mice irradiated and grafted with unfraction-
ated BM derived from GFP transgenic mice. Five weeks after trans-
plantation, BM engraftment was confirmed through flow cytometry
analysis. Moreover, among BM-engrafted cells, the MSC population
also replenished the BM, as assessed by MSC isolation from BM of
chimeric mice. The CFU-F assay revealed the presence of one-third
GFP+ MSCs within the BM of recipient mice (data not shown), thus
donor-derived, consistent with previously published studies [39,40].
At this time point, PDVA cells were subcutaneously injected into
mice flanks. The histologic examination of tumors harvested at
day 45 revealed the presence of spindle-shaped fibroblastic cells, orga-
nized in bundles in collagen-containing stromal septa infiltrating the
Figure 3. Expression of MMP13 by BM-derived myofibroblasts. (A,
B) MMP13 in situ hybridization demonstrated strong expression of
MMP13 mRNA by stromal cells invading the tumor, whereas stro-
mal cells bordering the tumor presented lower signal. (C, D) A com-
bination of α-SMA immunostaining and MMP13 in situ hybridization
revealed that MMP13 mRNA is expressed by myofibroblasts. (E, F)
α-SMA–positive myofibroblasts bordering the tumor express only
low amounts of MMP13 mRNA, whereas myofibroblasts within
the tumor mass do express high amounts of MMP13 mRNA. (G, H)
The expression ofMMP13 byGFP+ BM–derived cells was illustrated
by a combination of MMP13 in situ hybridization and GFP immuno-
staining. Representative images of in situ hybridization without and
combined with immunoperoxidase stainings are presented in bright
field (A, C, E, and G) and in dark field (B, D, F, and H); i, intratumoral;
p, peritumoral. The graphs correspond to the density of MMP13
mRNA labeling as a function of the distance to brown staining of (I)
α-SMA or (J) GFP. X90 (percentile) means that 90% of values are
below this distance.
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tumor and evidenced by saffron staining (Figure 1A). Morphologic
features of these tumors resembled the desmoplastic reaction usually
seen in human invasive skin carcinomas.
GFP-positive cells were observed in the entire tumor (Figure 1B ) and
mainly associated with the connective tissue bundles, as assessed by
combined immunostaining for GFP and saffron staining (Figure 1C ).
Flow cytometry analysis of the cell suspension obtained from enzymatic
tumor dissociation revealed that 23.7% of cells infiltrating the tumor
were GFP+-derived cells (insert in Figure 1B ). A large proportion of
theGFP+ cells (61%) were inflammatoryCD45+ cells (Figure 1D). Fur-
thermore, the following three different mesenchymal markers were used
to determine the proportion of the different stromal subpopulations that
originate from the BM: α-SMA for myofibroblastic cells (Figure 2A),
NG2 for pericytes (Figure 2B ), and Thy1 for fibroblastic-like cells
(Figure 2C ). A computer-assisted quantification method revealed that
α-SMA+ cell population contained at least 30% of GFP+ cells that were
BM-derived cells. A similar fraction of the GFP+ BM–derived cells were
positive for NG2, whereas only a small proportion (less than 10%) was
Thy1 immunoreactive (Figure 2D). These results demonstrate a
recruitment of CAFs from the BM and that each fibroblastic subset
consisted of a mixed population of cells obtained from BM-derived cells
and resident fibroblasts with Thy1+ cells mainly originating from local
cells. Notably, few if any double-positive (GFP/α-SMA, GFP/Thy1, or
GFP/NG2) cells were found in the normal skin (data not shown).
MMP13 Is Expressed by α-SMA–Positive Cells Derived
from the BM
We next analyzed the expression of MMP13 in BM-derived cells
through in situ hybridization using 35S-labeled MMP13 riboprobes.
MMP13 in situ hybridization was combined to α-SMA or GFP
immunostainings. For all samples, a corresponding sense probe was
used as negative control and showed only background signal (data
not shown). MMP13 mRNA was detected in all samples (n = 19)
and was localized in the stroma at invasive foci of the tumor (Figure 3,
A–D). A faint MMP13 mRNA staining was detected in the peri-
tumoral area, whereas a strong staining was found in intratumoral
stromal bundles (Figure 3, A and B ). When α-SMA immunostaining
was combined to MMP13 in situ hybridization, MMP13 mRNA
expression was exclusively detected in myofibroblasts infiltrating the
tumor (Figure 3, C–F ). GFP immunostaining combined to MMP13
in situ hybridization revealed that MMP13 mRNA was expressed by
BM-derived cells (Figure 3,G andH ). A computer-assisted quantification
method was used to determine the association between α-SMA– or
GFP-positive cells and the expression of MMP13 mRNA. The distri-
bution of MMP13 mRNAs in and around α-SMA– or GFP-positive
stromal compartment showed that 90% of MMP13 mRNAs are at
a distance maximum of 24.37 μm from GFP-positive cells (X90 =
24.37 μm) and 20.16 μm from α-SMA–positive cells (X90 = 20.16 μm).
These results therefore demonstrate that MMP13 is produced by BM-
derived α-SMA+ myofibroblasts (Figure 3, I and J ).
MSC-derived MMP13 Promotes Cancer Cell Invasion
In Vitro
With the aim to determine whether MSC-derived MMP13 could
influence cancer cell invasion, MSCs were isolated from mouse BM
and used in vitro. The expression of MMP13 was evaluated both
at the mRNA and protein levels in cultures of MSCs alone or with
PDVA cancer cells separated by a semipermeable membrane, allowing
the passage of secreted molecules. Both MMP13 mRNA and protein
levels of MSCs were significantly increased, when PDVA cells were
present (Figure 4). Western blot analyses revealed that both pro-form
of 60 kDa and an active species of 48 kDa were detected upon MSC
confrontation to soluble factors produced by cancer PDVA cells
(Figure 4B ). NomRNA for murine collagenase 1A, the mouse counter-
parts of human MMP1, was detected in MSC cultures, neither in the
absence nor in the presence of PDVA cells. MSCs expressed low levels
of MMP2 and MMP14 mRNAs that were not modulated upon con-
frontation to cancer cells (Figure 4A).
The putative pro-invasive effects of MSC-derived MMP13 on inva-
sive capacity of PDVA cancer cell were examined using an in vitro
Figure 4. Malignant keratinocytes stimulate MMP13 expression of MSC. (A) MSCs were cultured alone (MSC) or in the presence of an
insert containing PDVA cancer cells (MSC + PDVA). (A) RT-PCR analyses of different MMPs. Quantification of MMP13 mRNA levels
modulated upon MSC to cancer cell confrontation is expressed as a ratio between MMP13 mRNA and 28 rRNA (graph on the right
panel). A positive control (corresponding to murine placenta) is shown for MMP1a mRNA analysis (Ctl). (B) Western blot analysis of
MMP13 pro-form and active form expression by MSCs cultured with PDVA cells. Actin was used as a loading control.
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spheroid migration assay. MSCs were isolated from GFP+ mice, wild-
type mice, or MMP13-deficient mice. The production of MMP13 in
wild-type mice but not in MMP13-deficient mice was assessed at both
mRNA and protein levels (data not shown). When PDVA cells were
confronted with GFP+ MSCs in spheroids embedded in a collagen
gel, cancer cells sprouted into the matrix, whereas MSCs remained in
the spheroid (Figure 5A). Malignant cell invasion was significantly
enhanced in the presence of MSCs compared to PDVA cells cultured
alone (P = .0032; Figure 5, B and C ). Notably, the presence of MSCs
harvested from MMP13-deficient mice did not stimulate PDVA cell
migration in the spheroid assay, demonstrating the contribution of
MSC-derived MMP13 in PDVA cell migration (Figure 5, D and E ).
We also evaluated the impact of a broad-spectrum MMP inhibitor
(Batimastat or BB94). While BB94 reduced by 40% PDVA cell migra-
tion inmonoculture, a higher inhibition (57%, P < .05) was observed in
the presence of MSC (Figure 5F ).
Discussion
Carcinoma cells are not self-sustaining entities, but their proliferative
and invasive capacities are influenced by stromal cells derived from
several sources. Although CAFs are now recognized as a heterogeneous
Figure 5. MSC-derived MMP13 promotes cancer cell migration in a three-dimensional spheroid model. PDVA cells alone (PDVA) or
mixed with MSC (PDVA + MSC) were embedded as spheroids in a type 1 collagen matrix for 48 hours. MSCs were derived from (A)
GFP mice, (C) wild-type mice (MSC WT), or (D) MMP13-deficient mice (MSC KO). (A) Combination of fluorescent and phase contrast
images showed that GFP signal is detected in the spheroids composed of PDVA and GFP+ MSC but not in cells spreading out of the
spheroid. Optical microscopic observation of spheroids composed of PDVA alone (B) or confronted to MSC expressing (C) or not
MMP13 (D). (E) Quantification of tumor cell migration area of PDVA cells cultured alone or mixed with MSC WT or MSC KO. (F) Quan-
tification of PDVA cell migration area cultured alone or mixed with MSC, in the presence of BB94 or control.
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cell population, the correlation between their origin, phenotype, and
function remains unclear. Here, through the engraftment of GFP+
BM into mice, we show that 1) BM-derived cells infiltrate murine
skin carcinomas and generate inflammatory cells and CAFs positive
for α-SMA, NG2, or Thy1; 2) each fibroblastic population derives
from cells of two different origins, i.e., BM-derived progenitors and
tissue-resident cells; 3) at least one third of α-SMA– or NG2-positive
cells are BM-derived cells, whereas Thy1+ fibroblasts are primarily
derived from resident cells; 4) MMP13 is produced by BM-derived
α-SMA myofibroblasts; 5) MSC-derived MMP13 promotes cancer
cell invasion.
In accordance with previous reports [41], by providing evidence in
a murine skin carcinoma that the tumor stroma is composed of a com-
bination of host and BM-derived fibroblastic cells, our study supports
the concept that cancer is a systemic disease rather than a local dys-
function spreading from one tissue [42]. Through BM reconstitution
in mice, we demonstrate a massive recruitment of CAFs from the BM.
In contrast to previous published data [43,44], we show here that BM
MSC engraftment is possible as assessed by the capacity of BM derived
from chimeric mice to differentiate into mesenchymal cells. This obser-
vation is in line with the recent study of Quante et al. [40]. BM-derived
CAFs expressed a fibroblastic marker (Thy1), a myofibroblastic marker
(α-SMA), or a perivascular marker (NG2), indicating their contribu-
tion to the formation of both stromal septa andmicrovascular structures.
In amodel of chronic inflammation and gastric cancer progression, BM-
derived cells were shown to differentiate to CAFs [40], as also evidenced
in studies in other cancer models [45,46]. Recently, MSCs were also
demonstrated to be pericytic precursors [47]. Our data reveal that
around 30%of theα-SMA+myofibroblastic orNG2+ pericytic cells that
accumulate in the tumor-associated stroma are BM-derived, whereas
only 10% of Thy1+ fibroblast originate from the BM. Thy1 has been
described as amarker of undifferentiated fibroblasts [48]. Indeed, higher
α-SMAexpressionwas found inThy1-negative fibroblast subset, both at
baseline and in response to transforming growth factor–β activation [48].
The stimulation of human pulmonary fibroblast with interleukin-1 and
tumor necrosis factor–α promoted loss of Thy1 expression associated
with differentiation to a myofibroblast phenotype [49]. Therefore, our
results demonstrate that BM-derived cells contribute mainly to generate
reactive fibroblasts and pericytes associated to vascular component.
We next focused our interest on MMP13, which has been dem-
onstrated to be a key stromal mediator of cancer progression [29,50].
MMP13 is induced during invasion and metastasis of breast car-
cinoma, squamous cell carcinomas of the head and neck, and mela-
nomas [21–26]. The human form of MMP13 has been evidenced in
skin fibroblasts [51] and breast cancer cell–associated myofibroblasts
[22,28]. Its expression has also been detected in cancer cells at the
evading front. In accordance with previous reports [28,29], in situ
hybridization combined with immunostaining revealed that MMP13
is produced by myofibroblasts. Notably, we found that MMP13 is
produced by BM-derived myofibroblasts. This result, supported by
combined in situ hybridization and immunostainings, suggests for
the first time a specialization of a subpopulation of BM-derived CAFs
in the production of MMP.
The concept of BM-derived MSCs as the source of MMP13 during
cancer development is supported by in vitro experiments showing 1)
MSC basal expression levels of MMP13 mRNA and proteins, which
were strongly upregulated in co-culture with cancer cells; 2) the
enhancement of squamous cell carcinoma spheroid migration in a
collagen gel in the presence of wild-type but not MMP13-deficient
MSC; 3) the inhibition of MSC-mediated tumor cell migration by
a synthetic broad-spectrum MMP inhibitor. The pro-tumoral and
pro-angiogenic role of stromal MMP13 in skin carcinoma develop-
ment has previously been documented by subcutaneous injections
of BDVII SCC tumor cells into wild-type or MMP13-deficient mice
[29]. Similar results have also been reported for melanoma, where
host MMP13 contributed to tumor vascularization and invasion
[50]. Furthermore, in a model of choroidal neovascularization, we
have previously demonstrated a pro-angiogenic role of MMP13,
which was mediated by BM-derived mesenchymal cells [30]. In the
present study, we provide evidence for the contribution of BM-
derived cells to the constitution of the fibrovascular network and the
involvement of these cells in cancer progression through MMP13 pro-
duction. This work is in line with recent reports demonstrating the
implication of BM-derived CAFs in tumor cell invasion [12,40].
In conclusion, our study strengthens the crucial contribution of
BM-derived MSCs in cancer progression and invasion. The results
strongly support a novel concept of BM-derived CAF specialization
in tumor-supportive MMP production. Although MSCs have shown
some clinical promise in cancer treatment [41] and is attracting the
attention of researchers, the safety of such cell-based therapy that can
generate cells producing pro-tumorigenic and pro-invasive MMPs
must be assessed. Strategies that counteract MSC-cancer cell inter-
actions appear of therapeutic value to block tumor cell invasiveness.
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